About Denovo Biopharma
Denovo Biopharma is a company based in San Diego (United States) founded in 2013. Denovo Biopharma has raised $171.82 million across 4 funding rounds from investors including CICC, Qcc and CITIC. The company has 42 employees as of December 31, 2022. Denovo Biopharma operates in a competitive market with competitors including GSK, Metabolon, Avidity Biosciences, Sutro Biopharma and Maze Therapeutics, among others.
- Headquarter San Diego, United States
- Employees 42 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Denovo Biopharma Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$171.82 M (USD)
in 4 rounds
-
Latest Funding Round
$45.9 M (USD), Series D
Dec 08, 2020
-
Investors
CICC
& 13 more
-
Employee Count
42
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Denovo Biopharma
Unlock access to complete
Unlock access to complete
Funding Insights of Denovo Biopharma
Denovo Biopharma has successfully raised a total of $171.82M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $45.9 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Denovo Biopharma
Denovo Biopharma has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include CICC, Qcc and CITIC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A venture capital firm based in Shenzhen, China, is operated.
|
Locked | Locked | Locked | |
|
Investment bank & PE fund focused on multiple sectors
|
Locked | Locked | Locked | |
|
A venture capital firm focused on life sciences investments.
|
Locked | Locked | Locked |
Investor details for Denovo Biopharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Denovo Biopharma
Investment portfolio details for Denovo Biopharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Denovo Biopharma
Detailed financials for Denovo Biopharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Denovo Biopharma Comparisons
Peer comparison for Denovo Biopharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Denovo Biopharma
Denovo Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Metabolon, Avidity Biosciences, Sutro Biopharma and Maze Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Solutions for biomarker discovery and diagnostic testing are provided.
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Genetic biomarkers are developed for neurological, metabolic, and renal diseases.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
Detailed competitors of Denovo Biopharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Denovo Biopharma
Complete news archive for Denovo Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Denovo Biopharma
Denovo Biopharma was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Denovo Biopharma is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Denovo Biopharma is a funded company, having raised a total of $171.82M across 4 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Denovo Biopharma is 42.
Denovo Biopharma was founded in 2013 and is based in San Diego, United States. The company operates in the biopharmaceutical sector, where a genomic biomarker discovery platform is utilized to identify biomarkers for personalized drug development. This approach is applied across multiple therapeutic areas, including oncology, metabolic disorders, cardiology, immunology, and neurology, supporting targeted therapies in clinical applications.
Denovo Biopharma's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Denovo Biopharma has 14 investors. Key investors include CICC, Qcc, CITIC, Zhejiang Xianju Pharmaceutical, and Yingke Capital.